My Prediction: Note the following is filled with speculation only.
Histogen and Adreans will hit the market first.
The main competition will be between Adreans and Replicel.my assumption is Adreans knows Replicel are on their tail
hence the 150 million dollar investment, and I think they know Replicel have cracked it.
Histrogen maybe use for treating the early stages of balding, as its only known to reactivate existing dormant hair cells.
Replicel is known to create new hair follicles, that produce better results than DP CELLS. So this will be used to treat the nw6 7s maybe.
Follica Bio...
I really find it hard to make any assumptions about these guys, I mean Christ if you read there patents at one point it looks like there creating some computerized machine.
See excerpt
A method according to the present invention for promoting new hair growth a human scalp is performed as follows. A male subject with substantial hair loss on the scalp is seated in a stationary examination chair. A high-resolution digital camera is used to obtain an image of an area of the scalp measuring about 100 cm 2 . The image is stored onto the hard drive of a general purpose digital computer that is equipped with software for identifying physical features that are typically found on the scalp and for assigning coordinates to identified physical features that are based on the location of the physical feature relative to the margins of the imaged portion of the scalp. The computer identifies a first hair follicle by location of the point at which a detected terminal hair enters the scalp and records the likely location of the identified hair follicle, as well as the probable angle of the follicle in view of the angle of the terminal hair that is associated therewith.
An incision unit comprising an 5×5 array of fractional lasers is positioned so that one of the lasers is proximate to the identified hair follicle. Each unit of the 5×5 array is equipped with a laser for producing a fractional laser pattern, an angled “cage” that rests against the body surface in order to angle the laser so that it is applied to the body surface at an oblique angle when activated, and piezoelectric elements for directing individual beams. The system of which the incision unit is a part is controlled by a general purpose digital computer that accepts input regarding pertinent information from a human operator. The computer activates the incision unit, and each fractional laser produces a pattern of angled laser beams that are applied to the body surface. The computer controls the power of the lasers and the amount of time during which the laser is applied to the body surface so that each laser penetrates the body surface to a depth of 500 microns. The computer likewise controls the piezoelectric elements with respect to each beam in order to translate each beam relative to the body surface in a linear direction during application to the bodys surface, such that each beam produces a slit-like injury measuring 2 mm in length (and 500 microns deep, as specified above). The lasers are subsequently deactivated.
Next, the computer activates applicators that are integrated with the incision unit. The applicators each include an inkjet-type head for delivering a composition substantially directly into the wounds that were formed by the respective fractional beams. A small volume (about 50 μL) of a composition comprising 6-bromo-indirubin-3′-oxime (a GSK3β modulator) and carrier comprising PEO-PPO-PEO (a thermoreversible polymer that gels when exposed to human physiological temperatures) is delivered as a fluid into every third wound, and the applicators are deactivated.
The computer then uses the previously acquired image of the portion of the subject's scalp to permit a determination of the optimal direction in which the incision unit should be translated relative to the scalp. A human operator analyzes the image and determines that the remaining hairs on the subject's scalp are oriented in a clockwise whorl. The operator designates a direction in which the incision unit should be translated relative to the scalp in order to expose as many follicles at an appropriate angle to the incisors, and enters the appropriate information to the computer using an interface. The computer then directs the incision unit to a location relative to the subject's scalp that is consistent with the determination of the orientation of hair follicles. The computer then activates the incision unit, and each fractional laser produces a pattern of angled laser beams that are applied to the body surface. The computer controls the power of the lasers and the amount of time during which the laser is applied to the body surface so that each laser penetrates the body surface to a depth of 500 microns. The computer likewise controls the piezoelectric elements with respect to each beam in order to translate each beam relative to the body surface in a linear direction during application to the bodys surface, such that each beam produces a slit-like injury measuring 2 mm in length (and 500 microns deep, as specified above). The lasers are subsequently deactivated.
I actually think Follica is end game, I think their 10 to 20 years off, but when they do hit the market it will be with a drug or vaccine.
That being said really hard to know with those guys.
Histogen and Adreans will hit the market first.
The main competition will be between Adreans and Replicel.my assumption is Adreans knows Replicel are on their tail
hence the 150 million dollar investment, and I think they know Replicel have cracked it.
Histrogen maybe use for treating the early stages of balding, as its only known to reactivate existing dormant hair cells.
Replicel is known to create new hair follicles, that produce better results than DP CELLS. So this will be used to treat the nw6 7s maybe.
Follica Bio...
I really find it hard to make any assumptions about these guys, I mean Christ if you read there patents at one point it looks like there creating some computerized machine.
See excerpt
A method according to the present invention for promoting new hair growth a human scalp is performed as follows. A male subject with substantial hair loss on the scalp is seated in a stationary examination chair. A high-resolution digital camera is used to obtain an image of an area of the scalp measuring about 100 cm 2 . The image is stored onto the hard drive of a general purpose digital computer that is equipped with software for identifying physical features that are typically found on the scalp and for assigning coordinates to identified physical features that are based on the location of the physical feature relative to the margins of the imaged portion of the scalp. The computer identifies a first hair follicle by location of the point at which a detected terminal hair enters the scalp and records the likely location of the identified hair follicle, as well as the probable angle of the follicle in view of the angle of the terminal hair that is associated therewith.
An incision unit comprising an 5×5 array of fractional lasers is positioned so that one of the lasers is proximate to the identified hair follicle. Each unit of the 5×5 array is equipped with a laser for producing a fractional laser pattern, an angled “cage” that rests against the body surface in order to angle the laser so that it is applied to the body surface at an oblique angle when activated, and piezoelectric elements for directing individual beams. The system of which the incision unit is a part is controlled by a general purpose digital computer that accepts input regarding pertinent information from a human operator. The computer activates the incision unit, and each fractional laser produces a pattern of angled laser beams that are applied to the body surface. The computer controls the power of the lasers and the amount of time during which the laser is applied to the body surface so that each laser penetrates the body surface to a depth of 500 microns. The computer likewise controls the piezoelectric elements with respect to each beam in order to translate each beam relative to the body surface in a linear direction during application to the bodys surface, such that each beam produces a slit-like injury measuring 2 mm in length (and 500 microns deep, as specified above). The lasers are subsequently deactivated.
Next, the computer activates applicators that are integrated with the incision unit. The applicators each include an inkjet-type head for delivering a composition substantially directly into the wounds that were formed by the respective fractional beams. A small volume (about 50 μL) of a composition comprising 6-bromo-indirubin-3′-oxime (a GSK3β modulator) and carrier comprising PEO-PPO-PEO (a thermoreversible polymer that gels when exposed to human physiological temperatures) is delivered as a fluid into every third wound, and the applicators are deactivated.
The computer then uses the previously acquired image of the portion of the subject's scalp to permit a determination of the optimal direction in which the incision unit should be translated relative to the scalp. A human operator analyzes the image and determines that the remaining hairs on the subject's scalp are oriented in a clockwise whorl. The operator designates a direction in which the incision unit should be translated relative to the scalp in order to expose as many follicles at an appropriate angle to the incisors, and enters the appropriate information to the computer using an interface. The computer then directs the incision unit to a location relative to the subject's scalp that is consistent with the determination of the orientation of hair follicles. The computer then activates the incision unit, and each fractional laser produces a pattern of angled laser beams that are applied to the body surface. The computer controls the power of the lasers and the amount of time during which the laser is applied to the body surface so that each laser penetrates the body surface to a depth of 500 microns. The computer likewise controls the piezoelectric elements with respect to each beam in order to translate each beam relative to the body surface in a linear direction during application to the bodys surface, such that each beam produces a slit-like injury measuring 2 mm in length (and 500 microns deep, as specified above). The lasers are subsequently deactivated.
I actually think Follica is end game, I think their 10 to 20 years off, but when they do hit the market it will be with a drug or vaccine.
That being said really hard to know with those guys.
Comment